Anti-NFKB2 monoclonal antibody, clone FQS5797-77 Knockout Validated

Antibody Isotype

IgG

Clone

FQS5797-77

Species Reactivity

Mouse; Rat; Human

Immunogen

Recombinant fragment within Human NFkB p100/ p52. The exact sequence is proprietary.Database link: Q00653

Conjugate

Application Notes

IP: 1/10 - 1/100; WB: 1/10000 - 1/50000.

Alternative Names

NFKB2; nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100); nuclear factor NF-kappa-B p100 subunit; LYT 10; NF kB2; p52; p105; oncogene Lyt-10; DNA-binding factor KBF2; lymphocyte translocation chromosome 10 protein; nuclear fa

Entrez Gene ID

UniProt ID

Antigen Description

NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5-GGRNNYYCC-3, located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65.

Pathway

Activated TLR4 signalling, organism-specific biosystem; Alternative NF-kappaB pathway, organism-specific biosystem; Cytokine Signaling in Immune system, organism-specific biosystem; Cytosolic sensors of pathogen-associated DNA, organism-specific biosystem; DAI mediated induction of type I IFNs, organism-specific biosystem; Folate Metabolism, organism-specific biosystem; HTLV-I infection, organism-specific biosystem;